000			01729 a2200505 4500
005			20250516044545.0
264		0	_c20110913
008			201109s 0 0 ger d
022			_a1661-8157
024	7		_a10.1024/1661-8157/a000599 _2doi
040			_aNLM _beng _cNLM
100	1		_aBuck, G
245	0	0	_a[Osteoporosis]. _h[electronic resource]
260			_bPraxis _cJul 2011
300			_a821-32 p. _bdigital
500			_aPublication Type: Case Reports; Journal Article
650	0	4	_aAbsorptiometry, Photon
650	0	4	_aAged
650	0	4	_aAlgorithms
650	0	4	_aAntibodies, Monoclonal _xadverse effects
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aBone Density Conservation Agents _xadverse effects
650	0	4	_aCalcitonin _xadverse effects
650	0	4	_aCalcium _xadministration & dosage
650	0	4	_aDenosumab
650	0	4	_aDiphosphonates _xadverse effects
650	0	4	_aFemale
650	0	4	_aFemoral Neck Fractures _xdiagnosis
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aOrganometallic Compounds _xadverse effects
650	0	4	_aOsteoporosis, Postmenopausal _xdiagnosis
650	0	4	_aOsteoporotic Fractures _xdiagnosis
650	0	4	_aRANK Ligand _xadverse effects
650	0	4	_aRisk Factors
650	0	4	_aSelective Estrogen Receptor Modulators _xadverse effects
650	0	4	_aSpinal Diseases _xdiagnosis
650	0	4	_aTeriparatide _xadverse effects
650	0	4	_aThiophenes _xadverse effects
650	0	4	_aVitamin D _xadministration & dosage
700	1		_aPerger, L
700	1		_aBischoff-Ferrari, H A
773	0		_tPraxis _gvol. 100 _gno. 14 _gp. 821-32
856	4	0	_uhttps://doi.org/10.1024/1661-8157/a000599 _zAvailable from publisher's website
999			_c20984774 _d20984774